Adding dexmedetomidine to dexamethasone does not prolong analgesia in upper limb surgery
This randomized, placebo-controlled, triple-blind trial enrolled 100 patients undergoing upper limb surgery to evaluate whether adding i.v. dexmedetomidine 1 μg/kg to i.v. dexamethasone 0.15 mg/kg prolongs analgesia duration compared to dexamethasone alone. The primary outcome was duration of analgesia measured from block procedure to first oral opioid intake. The mean duration was 621 (334) minutes in the dexamethasone group and 690 (544) minutes in the dexamethasone-dexmedetomidine group, a difference that was not statistically significant (P=0.47). Secondary outcomes, including duration of sensory and motor blocks, pain scores, cumulative oral morphine consumption at 48 hours, and incidence of hypotension and bradycardia, also showed no significant differences between groups. Safety data were limited; serious adverse events and discontinuations were not reported. The study's limitations were not explicitly stated, but the small sample size and single-center design may affect generalizability. For clinicians, this evidence suggests that adding dexmedetomidine to dexamethasone does not provide a meaningful analgesic benefit in upper limb surgery, and routine use of this combination is not supported.